Company intelligence / Profile preview
Cardiol Therapeutics Inc.
Oakville, Ontario, Canadacardiolrx.com ↗
- Ownership
- Public · CRDL
- Employees
- ~18
- Development stage
- Other
01
Overview
Cardiol Therapeutics has shown positive Phase II data for CardiolRx in recurrent pericarditis, demonstrating marked reductions in pain, inflammation, and recurrence episodes. The company has advanced to Phase III MAVERIC trial for recurrent pericarditis and completed enrollment in Phase II ARCHER trial for acute myocarditis with topline data expected in Q2 2025. CardiolRx has received FDA Orphan Drug Designation for pericarditis treatment.
- Therapeutic areas
- Cardiovascular
- Modalities
- Small moleculesCannabidiol oral solutionSubcutaneous drug formulation
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Meros
04
Financials
- Market cap
- $111.8M
- Total revenue
- $0
- Enterprise value
- $93.3M
Beyond the preview
Go deeper on Cardiol Therapeutics Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cardiol Therapeutics Inc..